Compass Therapeutics (CMPX) Projected to Post Quarterly Earnings on Monday

Key Points

• Compass Therapeutics is set to announce its Q2 2025 earnings on August 11th, with analysts predicting a loss of ($0.13) per share.
• The company's stock recently traded down 1.9%, closing at $2.90, with a market capitalization of $400.32 million.
• Analyst ratings for Compass Therapeutics are largely positive, with a consensus rating of "Buy" and a price target averaging $12.67 per share.

Compass Therapeutics (NASDAQ:CMPX - Get Free Report) is projected to issue its Q2 2025 quarterly earnings data before the market opens on Monday, August 11th. Analysts expect Compass Therapeutics to post earnings of ($0.13) per share for the quarter.

Compass Therapeutics (NASDAQ:CMPX - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.12) EPS for the quarter, hitting analysts' consensus estimates of ($0.12). On average, analysts expect Compass Therapeutics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Compass Therapeutics Trading Down 2.2%

Shares of CMPX stock traded down $0.06 on Friday, reaching $2.72. The company's stock had a trading volume of 135,319 shares, compared to its average volume of 1,369,076. The stock's fifty day simple moving average is $2.70 and its 200-day simple moving average is $2.49. Compass Therapeutics has a 1 year low of $1.07 and a 1 year high of $4.08. The company has a market capitalization of $375.99 million, a price-to-earnings ratio of -6.65 and a beta of 1.49.

Analysts Set New Price Targets

CMPX has been the topic of several recent analyst reports. Guggenheim reduced their target price on shares of Compass Therapeutics from $12.00 to $10.00 and set a "buy" rating on the stock in a research note on Friday, May 9th. HC Wainwright reissued a "buy" rating and issued a $24.00 price objective on shares of Compass Therapeutics in a research note on Monday, April 21st. Raymond James Financial upgraded Compass Therapeutics to an "outperform" rating and set a $9.00 target price for the company in a research report on Tuesday, July 1st. Finally, D. Boral Capital reiterated a "buy" rating and issued a $32.00 price target on shares of Compass Therapeutics in a report on Monday, April 28th. Nine investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Buy" and an average price target of $12.67.

Hedge Funds Weigh In On Compass Therapeutics

A hedge fund recently bought a new stake in Compass Therapeutics stock. Strs Ohio acquired a new position in Compass Therapeutics, Inc. (NASDAQ:CMPX - Free Report) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 17,900 shares of the company's stock, valued at approximately $34,000. 68.43% of the stock is currently owned by hedge funds and other institutional investors.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.